Eric A. Jonasch, MD, MD Anderson Cancer Center
Articles by Eric A. Jonasch, MD, MD Anderson Cancer Center

Relapsed/Refractory Clear Cell RCC: Novel Treatment Strategies
ByBrian I. Rini, MD,Eric A. Jonasch, MD, MD Anderson Cancer Center,Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center,Bruno R. Bastos, MD, Miami Cancer Institute ,Stephanie A. Berg, DO Switching their focus to relapsed/refractory advanced clear cell renal cell carcinoma, key opinion leaders review treatment options in this setting.

Second-Line Treatment Armamentarium in Clear Cell RCC
ByBrian I. Rini, MD,Eric A. Jonasch, MD, MD Anderson Cancer Center,Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center,Bruno R. Bastos, MD, Miami Cancer Institute ,Stephanie A. Berg, DO Comprehensive insight to treatment options available in the second-line setting of advanced clear cell renal cell carcinoma.

Rationale Behind Discontinuing IO Therapy in Clear Cell RCC
ByBrian I. Rini, MD,Eric A. Jonasch, MD, MD Anderson Cancer Center,Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center,Bruno R. Bastos, MD, Miami Cancer Institute ,Stephanie A. Berg, DO Focused discussion on the rationale behind discontinuing (or continuing) immunotherapy for patients with advanced clear cell renal cell carcinoma.

Selecting Therapy for a Real-World Patient With Clear Cell RCC
ByBrian I. Rini, MD,Eric A. Jonasch, MD, MD Anderson Cancer Center,Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center,Bruno R. Bastos, MD, Miami Cancer Institute ,Stephanie A. Berg, DO Centering discussion on a patient scenario of advanced clear cell renal cell carcinoma, panelists reflect on how they would approach selecting first-line therapy.